Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232113 | 0.83 | ROCK2 (0.36) | PARP1ROCK2CCNCCDK8HASPIN | |
| SCHEMBL2825036 | 0.82 | F11 (0.36) | PARP1ROCK2F11F2PRSS1 | |
| SCHEMBL3823509 | 0.79 | CCNC (0.34) | PARP1ROCK2CCNCCDK8HASPIN | |
| SCHEMBL15272044 | 0.79 | F11 (0.34) | ROCK2F11F2PRSS1PRSS2 | |
| SCHEMBL22468496 | 0.79 | BTK (0.31) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1710393 | 0.79 | BTK (0.31) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2029210 | 0.75 | JAK2 (0.39) | PARP1ROCK2F11F2PRSS1 | |
| SCHEMBL5706992 | 0.74 | CDC7 (0.34) | PARP1ROCK2CCNCCDK8HASPIN | |
| SCHEMBL25436217 | 0.74 | SIRT3 (0.37) | PARP1 | |
| SCHEMBL4791070 | 0.72 | CA1 (0.40) | ROCK2F11F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-3068786-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | University Health Network (CA) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015070349-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | PARP1 2322/4885ROCK2 3690/4885CCNC 4031/4885 |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | PARP1 2930/4885ROCK2 3509/4885CCNC 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.